iX Biopharma's drug for treating male erectile dysfunction has just been approved for sale in Singapore.

Silcap10.20Silcap capsules are small and taken orally while Wafesil wafers (not available in S'pore) are placed under the tongue where the drug is absorbed into the blood vessels.The product, Silcap®, has obtained approval and registration by the Health Sciences Authority, says Singapore-listed specialty pharmaceutical company iX Biopharma.

There is already a variety of generic treatment options but Silcap® is designed as a novel small capsule, unlike existing alternatives which are typically delivered in tablet form.


Silcap® is the first capsule sildenafil product to obtain marketing approval in Singapore.

Silcap® is iX Biopharma’s second drug for the treatment of male erectile dysfunction after Wafesil®.

The latter is a novel dose form of sildenafil delivered using iX Biopharma’s proprietary WaferiX® drug delivery technology, a sublingual wafer that delivers drug actives safely, conveniently and rapidly into the blood stream.

iX Biopharma also supplies Silcap® and Wafesil® in Australia since obtaining approval and registration in 2018 from the Therapeutic Goods Administration (TGA), the regulatory authority in Australia.

EvanTan7.19Ms Eva Tan, Director, Corporate and Commercial Strategy of iX Biopharma, said: “We are delighted with the approval and registration of Silcap® in Singapore. Apart from offering a unique value proposition when compared to existing sildenafil products in the market, Silcap® ’s approval continues to reaffirm our ability to bring products successfully from clinical development to registration and launch.”


Silcap® is available in dosage strengths of 25 mg and 50 mg in pack sizes of 4, 8 and 12 capsules.

iX Biopharma will be preparing for marketing launch of Silcap® in Singapore.

As sildenafil drugs are classed as prescription medication in Singapore, Silcap® will be supplied via licensed medical practitioners.

iX Biopharma cited a study that said erectile dysfunction is a common condition affecting one in five men over the age of 40 years 1.

In a population-based survey conducted in Singapore on men greater than 30 years old, a prevalence rate of male erectile dysfunction of 51.3% was observed, whereas another study on the ageing population in the country reported a prevalence rate of 73.0% 2.

1 “Assessment and Management of Infertility at Primary Healthcare Level”, Academy of Medicine Singapore, 2013

2 “Male sexual dysfunction in Asia”, Asian Journal of Andrology, 2011


Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance, and these problems may be related to a wide variety of factors.

Erectile dysfunction is common among older men and is often associated with chronic illnesses including atherosclerosis, diabetes and depression. It is also associated with certain prescription medications and alcohol consumption.

Counter NameLastChange
AEM Holdings2.3700.030
Best World2.460-
Boustead Singapore0.945-0.015
Broadway Ind0.133-
China Aviation Oil (S)0.920-0.005
China Sunsine0.4200.005
ComfortDelGro1.480-
Delfi Limited0.895-
Food Empire1.260-
Fortress Minerals0.300-0.005
Geo Energy Res0.305-0.005
Hong Leong Finance2.500-
Hongkong Land (USD)3.1400.020
InnoTek0.5500.030
ISDN Holdings0.305-0.005
ISOTeam0.0440.001
IX Biopharma0.0420.001
KSH Holdings0.250-
Leader Env0.047-0.004
Ley Choon0.045-
Marco Polo Marine0.067-
Mermaid Maritime0.139-0.001
Nordic Group0.305-0.005
Oxley Holdings0.088-0.001
REX International0.133-0.003
Riverstone0.795-0.020
Southern Alliance Mining0.430-
Straco Corp.0.485-0.025
Sunpower Group0.2100.005
The Trendlines0.067-
Totm Technologies0.022-
Uni-Asia Group0.820-0.005
Wilmar Intl3.470-0.030
Yangzijiang Shipbldg1.740-0.010